A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
11/2001
11/25/2001	CA2309417A1 Apoptotic entities for use in treatment of endothelium dysfunction disorders
11/22/2001	WO2001088134A2 Novel human lipocalin homologs and polynucleotides encoding the same
11/22/2001	WO2001087882A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
11/22/2001	WO2001087879A1 New thiochromane derivatives and their use as thrombin inhibitors
11/22/2001	WO2001087854A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	WO2001087852A1 Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
11/22/2001	WO2001087851A1 Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
11/22/2001	WO2001087849A2 Modulators of tnf- alpha signaling
11/22/2001	WO2001087846A2 Tricyclic pyrazole derivatives as protein kinase inhibitors
11/22/2001	WO2001087842A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/22/2001	WO2001087841A1 Novel polymorph v of torasemide
11/22/2001	WO2001087836A1 Novel $g(b crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
11/22/2001	WO2001087835A1 Α crystalline form of perindopril tert-butylamine salt
11/22/2001	WO2001087823A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives
11/22/2001	WO2001087376A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/22/2001	WO2001087374A1 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087373A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087348A2 Multifunctional nanodevice platform
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087342A2 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087339A1 Antithrombotic agents
11/22/2001	WO2001087329A1 Liquid pharmaceutical composition containing an erythropoietin derivate
11/22/2001	WO2001087289A2 Propofol for treatment of sepsis
11/22/2001	WO2001087284A2 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087038A2 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
11/22/2001	WO2001087037A1 Methods for modulating the proliferation of hematopoietic cells
11/22/2001	WO2001055333A8 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
11/22/2001	WO2001036611A8 Process for the production of a reversibly inactive acidified plasmin composition
11/22/2001	WO2001036462A3 Protein c derivatives
11/22/2001	WO2001030969A8 Stanniocalcin proteins and nucleic acids and methods based thereon
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	US20010044537 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine
11/22/2001	US20010044536 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
11/22/2001	US20010044535 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
11/22/2001	US20010044453 Combination drug therapy for glycolipid storage diseases
11/22/2001	US20010044424 Peritoneal dialysis solution containing modified icodextrins
11/22/2001	DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2411369A1 Antithrombotic agents
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409699A1 Novel polymorph v of torasemide
11/22/2001	CA2409448A1 Methods for modulating the proliferation of hematopoietic cells
11/22/2001	CA2409445A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409225A1 Tricyclic pyrazole derivatives
11/22/2001	CA2408827A1 Novel human lipocalin homologs and polynucleotides encoding the same
11/22/2001	CA2408729A1 Delivery systems for treatment of vascular disease
11/22/2001	CA2408719A1 Antiproliferative drug and delivery device
11/22/2001	CA2408608A1 Antiinflammatory drug and delivery device
11/22/2001	CA2408408A1 Modulators of tnf- alpha signaling
11/22/2001	CA2407540A1 Propofol for treatment of sepsis
11/22/2001	CA2407469A1 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	CA2407222A1 New thiochromane derivatives and their use as thrombin inhibitors
11/21/2001	EP1156050A2 Substituted tricyclics useful in sPLA2 induced diseases
11/21/2001	EP1156049A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
11/21/2001	EP1155691A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155690A2 Anti-angiogenic compositions and method of use
11/21/2001	EP1155689A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155019A1 Substituted porphyrins
11/21/2001	EP1155000A1 2-aminopyridines containing fused ring substituents
11/21/2001	EP1154999A1 Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity
11/21/2001	EP1154796A1 Novel albumin-free factor viii formulations
11/21/2001	EP1154785A2 Inhibitors for use in hemostasis and immune function
11/21/2001	EP1049721B1 Synthetic polysaccharides, their method of production and pharmaceutical compositions containing same
11/21/2001	EP0900207B1 Pyrazinone thrombin inhibitors
11/21/2001	EP0773962B1 Antibodies which activate an erythropoietin receptor
11/21/2001	EP0706398B1 Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters
11/21/2001	CN1323314A Inhibitors of caspases
11/21/2001	CN1323301A Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors
11/21/2001	CN1323203A FC receptor modulators and uses thereof
11/21/2001	CN1322761A Animal hematoglobin and its extraction process and use
11/21/2001	CN1322759A Composition for stimulating megacaryocyte growth and differentiation and process thereof
11/21/2001	CN1322719A MYT1 kinase inhibitor
11/21/2001	CN1075078C Producing process of stem cell factor
11/21/2001	CN1075062C 乙酸衍生物 Acetic acid derivatives
11/21/2001	CN1074930C Tongshuanhuoluowan-medicine for thrombolysis and activating collaterals
11/20/2001	US6319937 Isoxazoline fibrinogen receptor antagonists
11/20/2001	US6319922 Propanoic acid derivatives
11/20/2001	US6319896 Adding aqueous solution of charged polymer to solution of purified protein to reduce intermolecular or intramolecular interactions between the positively and negatively charged domains whereby solubility of protein is increased
11/20/2001	US6319499 Administering amount of antibody or fragment thereof effective to activate endogenous activity of erythropoietin receptor in mammal, wherein antibody or fragment thereof interacts with peptide consisting of specified amino acid sequence
11/20/2001	US6319260 Method of endoscopic mucosal resection using mucopolysaccharide and local injection preparation
11/20/2001	CA2077691C Oxidation resistant thrombomodulin analogs
11/20/2001	CA2046126C 2-thienylglycidic derivative, process for its preparation and its use as synthesis intermediate
11/20/2001	CA2008116C Glycine derivatives
11/15/2001	WO2001085980A2 Enzymatic assays for screening anti-cancer agents
11/15/2001	WO2001085942A2 Cytoskeleton-associated proteins
11/15/2001	WO2001085917A2 A device
11/15/2001	WO2001085779A2 Protein complexes and assays for screening anti-cancer agents
11/15/2001	WO2001085762A2 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	WO2001085760A1 Thrombin inhibitors
11/15/2001	WO2001085755A1 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity
11/15/2001	WO2001085722A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
11/15/2001	WO2001085719A1 Ortho-substituted anthranilic acid amides and their use as medicaments
11/15/2001	WO2001085677A1 Amino acid derivatives and their use as medicines
11/15/2001	WO2001085671A2 Anthranyl amides and their use as medicaments
11/15/2001	WO2001085256A2 Critical illness neuropathy
11/15/2001	WO2001085227A2 Nitric oxide-releasing metallic medical devices

1 ... 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 ... 671